Clinical benefits of resistance assay for HIV-specific protease inhibitors: When to check and in whom? [4]

AIDS

Volumn 13, Issue 10, 1999, Pages 1278-1279

  Aizawa, S ^a   Gatanaga, H ^a   Ida, S ^a   Sakai, A ^a   Tanaka, M ^a   Takahashi, Y ^a   Hirabayashi, Y ^a   Oka, S ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR;

GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MAJOR CLINICAL STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION; RETROSPECTIVE STUDIES; RNA, VIRAL; TIME FACTORS; VIRAL LOAD;

EID: 0032807917     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199907090-00021     Document Type: Letter

References (5)